📰 Neil Kumar News
Page 8 - Neil Kumar News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Neil Kumar. Real-time updates on events, politics, business and more.
February 7, 2023
Cowen initiated coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Rating) in a research report report published on Monday morning, Briefing.com reports. The firm issued an outperform rating on the stock. Several other research analysts also recently weighed in on the stock. SVB Leerink decreased their target price on shares of BridgeBio Pharma from […]
December 1, 2022
Check out the latest episode of "The Pat & Aaron Show" on 95.3 WDAE with Pat Donovan & Aaron Jacobson.
December 1, 2022
Check out "The Pat & Aaron Show Injury Report" with Dr. Neil Kumar from the Florida Orthopedic Institute, as he calls in for the weekly segment. The topics include CJ Gardner-Johnson, Tristan Wirfs, Eddie Jackson, Najee Harris, and more.
November 3, 2022
03.11.2022 - - Reported positive preclinical data for its next-generation KRASG12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism in late lead optimization - Reported positive updated 12-month Phase 2 data ...
October 28, 2022
/CNW/ - Richardson Wealth Limited (Richardson Wealth), a wholly owned subsidiary of RF Capital Group Inc. (TSX: RCG) (RF Capital), is honoured to announce that...
September 28, 2022
Black, red, yellow and green can be spotted around the streets as Grand Final fever has spread around the city.
September 20, 2022
20.09.2022 - - The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four ... Seite 1
August 10, 2022
- NULIBRY is the first and only approved therapy in the United States (U.S.) and in Israel to treat patients with MoCD Type A, an ultra-rare, life...
August 10, 2022
10.08.2022 - - NULIBRY is the first and only approved therapy in the United States (U.S.) and in Israel to treat patients with MoCD Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival ... Seite 1
August 2, 2022
PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on...